Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Edwards Lifesciences obtains CE Mark for Sapien 3 valve

Edwards Lifesciences, a US-based medical equipment company, has obtained CE Mark approval in Europe for its Sapien 3 transcatheter aortic valve (TAV).


With this approval, the company is initiating the European launch of its most advanced transcatheter aortic valve.

The Sapien 3 (TAV) valve features and outer skirt, a cuff of fabric surrounding the valve frame, to provide a seal to address paravalvular leak. The device can be delivered through a low-profile 14-French expandable sheath.

The valve can be implanted through transfemoral, transapical or transaortic approaches. Once implanted, the discreet valve anchors in the aortic annulus.

In the two first-in-human feasibility studies, the device demonstrated elimination of significant paravalvular leak during transcatheter aortic valve implantation.

Edwards transcatheter heart valves corporate vice president Larry L Wood noted the European physicians have been eagerly awaiting the launch of the Edwards SAPIEN 3 valve, and the company is very excited to make it available today.

"It has a unique design intended to provide a simpler procedure, along with fewer post-procedural complications and a faster recovery for patients.

"Based on our clinical leadership in transcatheter heart valves, we believe the SAPIEN 3 valve’s characteristics and procedural refinements have the potential to transform TAVI for both physicians and patients," Wood added.

Edwards SAPIEN 3 valve is an investigational device in the US and is not yet available for sale in the country. The device is being studied in the PARTNER II trial.

Image: Edwards’ SAPIEN transcatheter heart valve Model 9000TFX and accessories. Photo: Courtesy of US Food and Drug Administration.